



Press release

Embion Technologies SA successfully raises Seed Round funding towards commercialization of first prebiotic ingredient

Ecublens, 01 April 2019

Embion Technologies SA, a Swiss EPFL spin-off in the rapidly growing field of prebiotics, successfully raises Seed Round Funding with renowned investors. Embion was able to attract strategic investors from three continents alongside the existing shareholders, underlying the company's ambition to become the relevant global player in its field. Andreas Weckherlin and Stephane Constant will join the board of directors of Embion and add their significant market experience for the new growth trajectory of the company.

Embion Technologies SA announces the completion of its seed round of funding led by private and institutional investors from Switzerland, United States and Asia. The raised capital will be used to enhance the market entry and scalability of Embion Technologies which focuses entering the commercialization of prebiotics; natural plant extracts that can modulate the human and animal microbiome.

The microbiome, the trillions of microscopic organisms that live within the human and animal body, have recently attracted the attention of the global scientific community, discovering evidence of their link to the immune system, brain functions and metabolism, connecting with disease such as obesity, IBS, autism, stress and cancer to name only a few.

Although new, the prebiotics market is rapidly growing with a 2019 market study by renowned in the healthy lifestyle products industry New Hope Network showing that prebiotics are the hottest microbiome ingredients at the moment, having had three consecutive years of doubling sales and growth of more than 120 percent.

Georgios Savoglidis, CEO of Embion Technologies, stated: "Our goal is to use our unique technology in order to enable better health for humans and animals through nutrition, and the advances in complimentary technologies, together with the unique capabilities of our technology will allow us to achieve that", continuing, "2018 was a year that we made considerable progress in all aspects of the business and this reflected in the trust that our investors put in us. The interest in our financing round was very high, we had to turn down some very attractive options on the way. But at this early stage of the business it is imperative to have the right people on board and that there is full alignment of expectations. Our focus now is to reach commercialization in the first identified market of prebiotics within the following months."

Andreas Weckherlin who will join the board of directors commented "Embion is uniquely positioned with an outstanding innovation for a phase of high growth trajectory. We are impressed by Embion's Team and expertise to make a difference in its field."

Also joining Embion's board will be Stephane Constant, CEO of Solevo group Switzerland, commenting: "Embion Technologies team is endeavoring a real breakthrough in the field of renewable resources, with the vision to extract value ingredients from our natural resources, including the huge pile that is currently wasted, at affordable costs. This talented team is making a difference".

About Embion Technologies

Embion Technologies, a biotechnology spin-off of the Swiss Federal Institute of Technology in Lausanne (EPFL) founded in 2016, is aiming to disrupt the food, feed and chemicals sectors by enabling the production of specialty and commodity products for these markets from renewable resources through its unique, infinitely scalable, platform processing technology, result of more than 10 years of research at EPFL.

For more information:

visit: <https://embiontech.com/>

or contact Georgios Savoglidis
gsavoglidis@embiontech.com